JPRN-UMIN000008688尚未招募未知
sefulness and safety of Omalizumab (anti-IgE monoclonal antibody) on oral immunotherapy for patients with severe food allergy - Usefulness and safety of Omalizumab (anti-IgE monoclonal antibody) on oral immunotherapy for patients with severe food allergy
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 5years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Decision of ineligibility by a physician.
研究者
相似试验
已完成
不适用
Efficacy and safety of omalizumab (anti-IgE monoclinal antibody) on oral immunotherapy for patients with cow's milk allergy (randomized control study)food allergyJPRN-UMIN000015545The Mami Mizutani foundation Kansai Medical University50
已完成
不适用
Efficacy and safety of omalizumab, an anti-IgE monoclonal antibody, in patients with seasonal allergic rhinitis: a systematic review.seasonal allergic rhinitisJPRN-UMIN000040561Showa University School of Medicine2,270
进行中（未招募）
1 期
A trial to see if anti-IgE (an antibody) will improve severe eczema that has not been cured by other types of medicineSevere eczema in childrenMedDRA version: 19.0 Level: LLT Classification code 10003641 Term: Atopic eczema System Organ Class: 100000004858MedDRA version: 19.0 Level: LLT Classification code 10014189 Term: Eczema allergic atopic System Organ Class: 100000004858EUCTR2010-020841-29-GBKing`s College London62
进行中（未招募）
不适用
Combination Therapy of Omalizumab and Allergen Immunotherapy for Moderate to Severe AsthmaAllergic AsthmaNCT06771934Qianfoshan Hospital60
招募中
2 期
Treatment with Omalizumab in Psoriatic PatientsIRCT20150716023235N18Mashhad University of Medical Sciences20